A groundbreaking study has shed light on the potential benefits of a triplet combination involving brentuximab vedotin (BV) for patients with diffuse large B-cell lymphoma (DLBCL). The study demonstrated that this combination therapy, consisting of BV, lenalidomide, and rituximab, led to significant improvements in overall survival (OS) compared to lenalidomide-rituximab alone in the third-line setting.
Carlo Ancelotti’s Real Madrid completed a remarkable feat by clinching their 15th Champions League title with a 2-0 victory over Borussia Dortmund at Wembley. This win, coupled with their LaLiga triumph, marked a perfect season for the club. Despite facing tough challenges and losing key players, Ancelotti’s side showcased resilience and determination on their path